Synairgen had peer-reviewed data from the Company’s SG016 trial published in The Lancet Respiratory Medicine journal on 12 November 2020. The SG016 trial randomised 101 hospitalised COVID-19 patients to either SNG001, Synairgen’s inhaled formulation of interferon beta-1a, or placebo. Positive topline results from the trial were originally announced on 20 July 2020, with more detailed results of primary endpoint analyses disclosed in the Company’s 2020 Interim Results on 29 September 2020.
The full title of the publication in the Lancet Respiratory Medicine is: “Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial”, and can be accessed here.
The Home Study arm of SG016 completed its planned enrolment of 120 COVID-19 patients on 19 January 2021.
Synairgen’s Phase III Trial (SG018) evaluating inhaled interferon beta in hospitalized COVID-19 patients is currently underway. The trial is a randomised, placebo-controlled study being conducted in approximately 20 countries enrolling a total of 610 COVID-19 patients.